EQUILUS THERAPEUTICS



# ADVANCING BREAKTHROUGH THERAPEUTICS FOR CNS DISORDERS

Public Information Overview

WHAT WE DO

# Advancing breakthrough therapeutics for central nervous system disorders

"Our vision at EQUULUS Therapeutics is to turn the promise of psychedelics into real-world therapeutics that transform patients' lives and set a new standard in neuroscience healthcare.“

— **Bob Discordia**, Co-founder & CEO

**48.5M**

Annual **addiction** cases in the US

**13M**

Annual cases of **PTSD** in the US

**2.9M**

Adults in the US with **active epilepsy**

**21M**

Adults in the US with **depression**

**Source:** HHS, NIMH NDA, CDC, USVA

OPPORTUNITY

# Effective treatments for CNS disorders remain a critical, unmet need

CNS disorders contribute to **more disability-adjusted life years (DALYs)** than any other disease category.

**$800B+**

Annual healthcare cost of CNS disorders

**$1.5T**

Annual cost to the US economy of CNS diseases

**443M**

Annual DALYs contributed by CNS disorders

**1 in 3**

Of people are affected by neurological conditions




**Sources:** NeuroToday, ITIF, Lancet, NIH NIDA, JAMA, NIMH

MARKET

# CNS therapeutics are a $117B market, projected to double by 2034

Neurological disorders are the leading cause of disability worldwide, affecting **over 3 billion people**

Patients with mental health or substance use disorder accounted for **over 30% of total US health care** spending

Current CNS therapeutics are **often ineffective**, focus on symptoms, and/or have serious side effects

**Failure rates for new CNS disorder drugs** are very high relative to most other areas of drug discovery




**Sources:** Precedence, Biospace, Grandview, Statista, WHO, Neuropharm, NIH

EQUULUS' **transdiagnostic approach** increases success rates, accelerates approvals, and amplifies value: a single therapeutic can address multiple conditions by targeting shared biologic pathways

WHY NOW

# Psychedelics are at a critical juncture




✗ **Irrational exuberance**: psychedelics viewed as a panacea

✗ **"First-gen" psychedelics** lack scalability, safety & IP protection

✓ **NCEs** solve for scalability, patient safety, & proprietary IP

✓ Focused on indications with **large unmet clinical needs**

✓ **De-risked IP** with tested pre-clinical safety profile

✓ Proven team of **experts in clinical drug development**

OUR DIFFERENCE

# Transdiagnostic development

Transdiagnostic development recognizes shared symptoms; **challenges the boundaries of traditional diagnostic silos**.

Overlapping symptoms suggest overlapping neurobiological circuits, such as…

- ✓ Stress response systems
- ✓ Behavioral regulation
- ✓ Negative emotions
- ✓ Reward pathways




EXAMPLES

### Cognitive enhancers

Agents enhancing prefrontal cortex function may improve behavioral regulation & goal-directed behavior.

### Emotional regulation therapies

Drugs modulating glutamate or serotonergic systems could address irritability and emotional numbness.

### Sleep-focused interventions

Pharmacological agents targeting GABAergic or melatonin pathways might alleviate sleep disturbances across all three disorders.

TRACTION

# Uniquely positioned with proprietary data and validated lead candidates

Early proof of concept and expedited paths to large pharma partnerships position our assets as **“acquisition-ready” from day one**

Küleon BIOSCIENCE

RTI INTERNATIONAL

UT Health San Antonio

NIH NIDA NATIONAL INSTITUTE ON DRUG ABUSE

Filed **six provisional patent** applications and **two PCT** applications



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 June 2023 (29.06.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/122135 A1

(51) International Patent Classification:
*C07D 517/14* (2006.01) *A61K 31/55* (2006.01)

(21) International Application Number:
PCT/US2022/053583

(22) International Filing Date:
21 December 2022 (21.12.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/292,567 22 December 2021 (22.12.2021) US
63/301,196 20 January 2022 (20.01.2022) US

(71) Applicant: **KULEON LLC** [US/US]; 5608 17th Avenue NW, Suite 1492, Seattle, Washington 98107 (US).

(72) Inventor: **GILLES, David**; c/o PsiloSterics, LLC, 5608 17th Avenue NW, Suite 1492, Seattle, Washington 98107 (US).

Formula VIIIa

Formula VIIIb

TEAM

# Experts in drug discovery, development & commercialization

Co-Founder, CEO

**Robert Discordia**, PhD

Chief Business Officer

**Drew Mouton**, MBA, MGM

Co-Founder, Medicinal Chemistry

**Bruce Blough**, PhD

Co-Founder, Clinical Psychology

**Peter Hendricks**, PhD

Co-Founder, Neuropharmacology

**Kevin Murnane**, PhD

ADVISORS

# Scientific advisory board

**Richard Shelton, MD**

Senior Medical Advisor

THE UNIVERSITY OF ALABAMA AT BIRMINGHAM

**Bruce Car, DVM, PhD**

Senior Scientific Advisor

biohaven

**John Renger, PhD**

Senior Neuroscientific Advisor

cerevel

**Angela Hargrove, MHA**

Sr. Scientific Advisor

FIRST COAST RESEARCH CENTER

**Pamela Perry, MS**

Senior Clinical Advisor

cerevel

**Neal Naito, MD, MPH**

Senior Medical Advisor

MVK PHARMACEUTICALS

**Andrew Riley, PhD**

Senior Scientific Advisor

UIC UNIVERSITY OF ILLINOIS CHICAGO

ASSETS

# Programs at EQUULUS

| | Asset | Stage | Primary Indication(s) | Milestone† |
|---|---|---|---|---|
| * | **MDMA Analog** | Discovery | PTSD | Candidate Selection 2027 |
| * | **Fenfluramine / Fen-Phen Analog** | Discovery | Seizure Disorders/ Obesity | Candidate Selection 2027 |
| | **EQL-101** | Candidate Selection | Substance Use Disorders; PTSD | Phase-1/2a start Q4 2026 / Q1 2027 |
| | **Confidential In-License** | IND-Enabling (Pre-Phase I) | Acute Suicidality (ER, Inpatient); Adjunctive MDD | Phase-1 2026 |

* 5HT Releaser Technology || NCE Platform

† Assumes successful funding Q4/25

# 5HT Releaser Technology NCE Platform

MDMA & Fenfluramine/FenPhen Analogs



TECHNOLOGY

# 5HT Releaser Technology NCE Platform

Library* of over 1400 small molecule neurotransmitter releasers representing 12 chemotypes

## COMPOUNDS

- Serotonin selective releasers
- Serotonin/Norepinephrine releaser
- Dopamine/Serotonin/Norepinephrine

*Differing profiles of $5HT_{2A}$ / $5HT_{2C}$ agonist activity*

## TARGET INDICATIONS

| | |
|---|---|
| **PTSD/Anxiety** | MDMA analog |
| **Epilepsy** | Fenfluramine analog |
| **Obesity** | Fen-Phen analog |
| **Addiction** | Proof-of-concept analog |

### Multiple Drug Candidates

Derisked compounds with advanced safety data and druggable properties.

### Accelerated Path

Targeting indications and advanced lead candidates with faster path to approval.

### High Barrier to Entry

Existing platform represents a decade of work and >$10M of investment.

### Cardio-safe

Many compounds with no $5\text{-}HT_{2b}$ receptor activity exist in all 12 chemotypes.

### Proprietary Data

Difficult to obtain dopamine, serotonin, and norepinephrine transporter data.

### Cost-efficient IP

Co-founder's proprietary knowledge and SAR expertise accelerate NCE discovery.

* Library built by co-founder Dr. Bruce Blough

# 5HT Releaser Technology Platform

**MDMA Analog**:

- Our MDMA-inspired, discovery stage, small molecule is being designed to preserve pro-extinction and pro-social neuroplasticity benefits for the treatment of PTSD while minimizing stimulant load, hyperthermia risk, and abuse liability.
- Through structure–activity optimization, we aim to decouple therapeutic signaling from unwanted effects for a cardio-safer, non-hallucinogenic profile.
- **Next Milestone**: *Candidate Selection*




**Fenfluramine Analog**:

- Our next-generation fenfluramine-class agent is being designed to retain seizure-modifying and appetite-regulating efficacy while reducing historical cardiovascular liabilities associated with legacy fenfluramine.
- Through structure–activity optimization, the medicinal chemistry is focused on selective serotonergic modulation and improved developability to support use in seizure disorders such as epilepsy and obesity.
- **Next Milestone**: *Candidate Selection*



# Ibogaine Analog Program

EQL-101

# Ibogaine analog program: EQL-101

EQUULUS is developing a safe, non-hallucinogenic, non-addictive therapy that will rapidly and dramatically reduce cravings and withdrawal symptoms in substance use disorders and PTSD.

## Ibogaine

- ✓ Potent and effective substance for addiction
- x Highly hallucinogenic
- x Cardiotoxic with reported fatalities
- x Cannot be patented as COM



Ibogaine

## 18-MC: a synthetic ibogaine analog

- ✓ Potent and effective substance for addiction (pre-clinical)
- ✓ Non-hallucinogenic (clinical)
- ✓ Non-cardiotoxic (clinical)
- x Highly complex metabolism
- x Primary patents expired



18-MC

## EQL-101

**Equulus is the only company developing an ibogaine analog aimed at being:**

- ✓ Effective substance for addiction
- ✓ Non-hallucinogenic (clinical evidence)
- ✓ Non-cardiotoxic (clinical evidence)
- ✓ Scalable
- ✓ Commercializable through FDA
- ✓ 6 provisional patents and 2 PCT patents filed

VALUATION

# Equulus as the Next Gilgamesh

| Success Factor | Gilgamesh Pharma | Equulus Therapeutics |
|---|---|---|
| Scientific Innovation | Novel psychoplastogens & ibogaine analogs | Non-hallucinogenic ibogaine analog (EQL-101) |
| Clinical Progress | Phase 2a (94% remission); milestone-linked deal | Stealth-emerged preclinical pipeline |
| Leadership & Expertise | Established, proven drug development team | Distinguished team, strong CNS biotech backbone |
| External Validation | Fierce 15, AbbVie deal talks (~$1B+ milestone) | Early attention in psychedelic and neuroscience biotech community |
| Exit Potential | Acquisition in progress | Positioned for high-value partnership trajectory |

*"Like Gilgamesh before us, Equulus is harnessing the next generation of psychoplastogens to deliver breakthrough CNS therapies—with the potential for transformative clinical results and strategic exits."*

HIGHLIGHTS

# Join Equulus in developing effective, modern therapeutics for CNS disorders

### Portfolio of Novel Assets

Highly competitive ibogaine analog with robust COM patents & 5HT Releaser NCE Platform.

### Large Indications

Addressing unmet clinical needs for chronic indications with multi-billion-dollar market demand.

### Transdiagnostic Approach

Increases development success rates with high-value therapeutics for several indications.

### World-Class Team

Industry & academic experts: led 200+ combined CNS clinical trials, multiple INDs and NDAs.

### Robust IP Strategy

Filed six provisional patent applications and two PCT applications.

CONTACT US

**Bob Discordia**

Co-founder & CEO

bdiscordia@equulus.com